| Dec'19 | Dec'18 | Dec'17 | Dec'16 | |||
|---|---|---|---|---|---|---|
Cash flows from operating activities: | ||||||
Net loss | ||||||
-40,454 | -64,831 | -7,525 | -14,766 | |||
Adjustments to reconcile net loss to net cash used in operating activities: | ||||||
Depreciation | ||||||
3,388 | 3,309 | 3,591 | 5,702 | |||
Amortization of intangible assets | ||||||
6,043 | 3,669 | 2,037 | 1,617 | |||
Non-cash interest expense | ||||||
243 | 845 | 410 | 1,662 | |||
Deferred interest expense | ||||||
1,446 | 249 | 233 | 108 | |||
Deferred rent expense | ||||||
882 | 56 | 70 | -26 | |||
Impairment of notes receivable | ||||||
- | - | 113 | - | |||
Write-off of deferred offering costs | ||||||
0 | 3,494 | - | - | |||
Provision (benefit) recorded for sales returns and doubtful accounts | ||||||
239 | 1,157 | 1,166 | 25 | |||
Deferred tax benefit (expense) | ||||||
111 | 186 | -7,301 | - | |||
Loss on disposal of property and equipment | ||||||
-146 | -1,209 | 8 | 9 | |||
Provision recorded for inventory reserve | ||||||
1,297 | 2,473 | 3,170 | 7,472 | |||
Stock-based compensation | ||||||
936 | 1,075 | 919 | 473 | |||
Change in fair value of warrant liability | ||||||
0 | 469 | 1,037 | 737 | |||
Loss on extinguishment of debt | ||||||
-1,862 | -2,095 | - | - | |||
Change in fair value of interest rate swap | ||||||
- | - | 6 | -253 | |||
Changes in fair value of forfeiture rights | ||||||
0 | 589 | -212 | - | |||
Changes in operating assets and liabilities: | ||||||
Accounts receivable | ||||||
4,691 | 7,110 | 7,010 | 6,556 | |||
Inventory | ||||||
11,063 | 1,524 | 1,490 | 5,367 | |||
Prepaid expenses and other current assets | ||||||
625 | 1,414 | 2,680 | -1,009 | |||
Accounts payable | ||||||
4,700 | -60 | 3,967 | 33 | |||
Accrued expenses and other current liabilities | ||||||
2,942 | 2,354 | 2,665 | 1,110 | |||
Accrued interest - affiliate debt | ||||||
0 | 9,241 | -3,190 | -2,339 | |||
Other liabilities | ||||||
-930 | 316 | 159 | 35 | |||
Net cash used in operating activities | ||||||
-33,528 | -60,635 | -3,493 | -4,871 | |||
Cash flows from investing activities: | ||||||
Purchases of property and equipment | ||||||
5,984 | 1,857 | 2,426 | 1,361 | |||
Acquisition of intangible asset | ||||||
250 | - | - | - | |||
Proceeds from disposal of property and equipment | ||||||
0 | 1 | 8 | 115 | |||
Acquisition of NuTech Medical, net of cash acquired | ||||||
- | - | 11,790 | - | |||
VIE deconsolidation | ||||||
- | - | 666 | - | |||
Net cash used in investing activities | ||||||
-6,234 | -1,856 | -14,874 | -1,246 | |||
Cash flows from financing activities: | ||||||
Line of credit borrowings | ||||||
7,000 | 8,866 | 12,749 | -2,399 | |||
Proceeds from term loan | ||||||
50,000 | - | 0 | - | |||
Proceeds from long-term debt - affiliates | ||||||
0 | 15,000 | - | 17,204 | |||
Proceeds from notes payable - master lease | ||||||
- | - | 16,000 | - | |||
Proceeds from equity financing | ||||||
50,340 | 92,000 | - | - | |||
Payment of equity issuance costs | ||||||
2,973 | 270 | - | - | |||
Repayment of mortgage notes payables—Real Estate Entities, net | ||||||
- | - | 1,335 | - | |||
Notes payables—related party borrowings (repayment), net | ||||||
- | - | - | 2,398 | |||
Repayment of debt and debt issuance cost on affiliate debt | ||||||
- | 22,680 | - | - | |||
Payment of recapitalization costs | ||||||
0 | 11,206 | - | - | |||
Repayment of notes payable | ||||||
17,585 | 10 | 6,325 | 5,250 | |||
Distributions to non-controlling interest in affiliates | ||||||
- | - | - | 5,200 | |||
Borrowing from affiliates | ||||||
- | - | - | 23 | |||
Proceeds from the exercise of stock options | ||||||
269 | 119 | 221 | - | |||
Redemption of redeemable common stock placed into treasury | ||||||
6,762 | - | - | - | |||
Principal repayments of capital lease obligations | ||||||
1,266 | 104 | 81 | - | |||
Proceeds from the exercise of common stock warrants | ||||||
628 | - | - | - | |||
Cash contributions from members of affiliates | ||||||
- | - | 1,000 | - | |||
Payment of deferred acquisition consideration | ||||||
- | - | 2,500 | - | |||
Payment of debt issuance costs | ||||||
924 | 177 | 862 | - | |||
Net cash provided by financing activities | ||||||
78,727 | 81,538 | 18,867 | 6,776 | |||
Change in cash and restricted cash | ||||||
38,965 | 19,047 | 500 | 659 | |||
Supplemental disclosure of cash flow information: | ||||||
Cash paid for interest | ||||||
8,148 | 5,423 | 6,076 | 3,965 | |||
Cash paid for income taxes | ||||||
49 | 8 | 96 | 29 | |||
Supplemental disclosure of non-cash investing and financing activities: | ||||||
Fair value of shares issued in connection with investor debt settlement | ||||||
- | 42,764 | - | - | |||
Fair value of shares issued in connection with settlement of investor warrants | ||||||
- | 2,707 | - | - | |||
Common stock issued in exchange for APHAC shares | ||||||
- | 1 | - | - | |||
Notice of put option exercise of redeemable common shares | ||||||
- | 6,762 | - | - | |||
Non-cash deemed dividend related to warrant exchange | ||||||
645 | - | - | - | |||
Fair value of warrant issued in connection with Subordinated Notes | ||||||
- | - | - | -464 | |||
Debt issuance costs included in accounts payable | ||||||
537 | - | - | 680 | |||
Purchases of property and equipment included in accounts payable and accrued expenses | ||||||
4,014 | 172 | 764 | 63 | |||
Acquisition of intangible assets included in accrued expenses and other liabilities | ||||||
500 | - | - | - | |||
Equipment acquired under capital lease | ||||||
1,099 | - | - | - | |||
Fair value of warrant issued in connection with notes payable | ||||||
- | - | 959 | - | |||
Extinguishment of Subordinated Notes - affiliates | ||||||
- | - | 4,577 | - | |||
Accretion of redeemable common stock | ||||||
- | - | 423 | - | |||
Shares issued in connection with NuTech Medical acquisition | ||||||
- | - | 16,609 | - | |||
Deconsolidation of variable interest entities, net of cash | ||||||
- | - | 9,052 | - | |||
Issuance of deferred acquisition consideration | ||||||
- | - | 7,500 | - | |||
Issuance of contingent consideration forfeiture rights | ||||||
- | - | 377 | - | |||